237 related articles for article (PubMed ID: 17691211)
1. Acceptance criteria for levels of hydrazine in substances for pharmaceutical use and analytical methods for its determination.
Kean T; Miller JH; Skellern GG; Snodin D
Pharmeur Sci Notes; 2006 Dec; 2006(2):23-33. PubMed ID: 17691211
[TBL] [Abstract][Full Text] [Related]
2. A liquid chromatographic method using a reversed-phase hybrid stationary phase to control potential impurities of imipramine hydrochloride.
Dixon SP; La Torre F; Lodi A; Miller JH; Skellern GG
Pharmeur Sci Notes; 2006 Dec; 2006(2):35-9. PubMed ID: 17691212
[TBL] [Abstract][Full Text] [Related]
3. Determination of the impurity profile of adenosine by means of ion-pair reversed-phase chromatography.
Kopec S; Almeling S; Holzgrabe U
Pharmeur Sci Notes; 2006 Dec; 2006(2):17-21. PubMed ID: 17691210
[TBL] [Abstract][Full Text] [Related]
4. Impurity profile of amino acids?
Kopec S; Holzgrabe U
Pharmeur Sci Notes; 2005 Aug; 2005(1):39-45. PubMed ID: 17687893
[TBL] [Abstract][Full Text] [Related]
5. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products.
Elder DP; Snodin D; Teasdale A
J Pharm Biomed Anal; 2011 Apr; 54(5):900-10. PubMed ID: 21145684
[TBL] [Abstract][Full Text] [Related]
6. Batch variability of bacitracin: HPLC versus MEKC.
Weber C; Matingen S; Holzgrabe U
Pharmeur Sci Notes; 2005 Aug; 2005(1):47-51. PubMed ID: 17687894
[TBL] [Abstract][Full Text] [Related]
7. Relationship between HPLC precision and number of significant figures when reporting impurities and when setting specifications.
Agut C; Segalini A; Bauer M; Boccardi G
J Pharm Biomed Anal; 2006 May; 41(2):442-8. PubMed ID: 16472956
[TBL] [Abstract][Full Text] [Related]
8. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
Giordani A; Kobel W; Gally HU
Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
[TBL] [Abstract][Full Text] [Related]
9. Development of an enhanced separation of erythromycin and its related substances by liquid chromatography.
Deubel A; Holzgrabe U
J Pharm Biomed Anal; 2007 Jan; 43(2):493-8. PubMed ID: 16935448
[TBL] [Abstract][Full Text] [Related]
10. Analytical methods for residual solvents determination in pharmaceutical products.
Grodowska K; Parczewski A
Acta Pol Pharm; 2010; 67(1):13-26. PubMed ID: 20210075
[TBL] [Abstract][Full Text] [Related]
11. A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS.
Sun M; Bai L; Liu DQ
J Pharm Biomed Anal; 2009 Feb; 49(2):529-33. PubMed ID: 19097722
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the recovery spread in analytical development and routine quality control--based on the ICH quality guideline Q2B.
Schepers U; El Deeb S; Ermer J; Wätzig H
J Pharm Biomed Anal; 2007 Jan; 43(2):708-10. PubMed ID: 16904281
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
14. Alternatives to amino acid analysis for the purity control of pharmaceutical grade L-alanine.
Holzgrabe U; Nap CJ; Beyer T; Almeling S
J Sep Sci; 2010 Aug; 33(16):2402-10. PubMed ID: 20549666
[TBL] [Abstract][Full Text] [Related]
15. Validation of analytical methods involved in dissolution assays: acceptance limits and decision methodologies.
Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P
Anal Chim Acta; 2012 Nov; 751():44-51. PubMed ID: 23084050
[TBL] [Abstract][Full Text] [Related]
16. Impurity profiling of pharmaceuticals by thin-layer chromatography.
Ferenczi-Fodor K; Végh Z; Renger B
J Chromatogr A; 2011 May; 1218(19):2722-31. PubMed ID: 21255781
[TBL] [Abstract][Full Text] [Related]
17. Determination of inorganic pharmaceutical counterions using hydrophilic interaction chromatography coupled with a Corona CAD detector.
Huang Z; Richards MA; Zha Y; Francis R; Lozano R; Ruan J
J Pharm Biomed Anal; 2009 Dec; 50(5):809-14. PubMed ID: 19616396
[TBL] [Abstract][Full Text] [Related]
18. Effect of incomplete removal of the tert-butoxycarbonyl protecting group during synthesis of a pharmaceutical drug substance on the residual solvent analysis.
Beilin E; Baker LJ; Aikins J; Baryla NE
J Pharm Biomed Anal; 2010 Jun; 52(2):316-9. PubMed ID: 20116957
[TBL] [Abstract][Full Text] [Related]
19. USP general chapter <797> pharmaceutical compounding-sterile preparations.
Hung JC
J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
[No Abstract] [Full Text] [Related]
20. Examination of microbiological quality of pharmaceutical raw materials.
Bomblies L; Weiss C; Beckmann G
Pharmeur Sci Notes; 2007 Sep; 2007(1):1-7. PubMed ID: 17993088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
